Posters Presented at 2024 CCA Summit

Numerous informative and engaging posters were showcased at the 2024 CCA Summit. There were 3 posters presented highlighting clinical trials in immunotherapy and included “Liver-Resident CAR T Cells With Enhanced Function Refractory ICC,” which found that organ-directed targeting of tumor-associated antigen–specific CAR T cells is a promising approach to treat refractory cancers involving the liver while avoiding off-tumor toxicities, and “Immune-Modulatory Effects of APOBEC3 in Cholangiocarcinoma: A Potential Immunotherapy Biomarker,” which investigated whether APOBEC3 expression is associated with tumor immune profiles that could facilitate a response to immunotherapy. In addition, investigators aimed to identify APOBEC3-induced cholangiocarcinoma (CCA) driver mutations that may influence the tumor immune microenvironment. Another poster, titled “Zanidatamab in Previously Treated HER2-Positive (HER2+) Biliary Tract Cancer (BTC): Overall Survival (OS) and Longer Follow-Up From the Phase 2b HERIZON-BTC-01 Study,” reported the updated analysis, including overall survival (OS), of the phase 2b HERIZON-BTC-01 study.

In the chemotherapy/immunotherapy landscape, there were 3 posters presented. “Immunotherapy in Complex Terrain: Outcomes in Cholangiocarcinoma With Background of Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases” found that chemoimmunotherapy in patients with CCA with a background of primary sclerosing cholangitis (PSC) and/or inflammatory bowel disease (IBD) may be safe and effective in those without active PSC and/or IBD. Another poster, titled “A Phase 3, Randomized Study of Adjuvant Rilvegostomig Plus Chemotherapy in Resected Biliary Tract Cancer: ARTEMIDE-Biliary01,” assessed the efficacy and tolerability of rilvegostomig plus chemotherapy as adjuvant treatment in patients with BTC after curative intent resection. The poster titled “Subsequent Anticancer Therapy (SAT) Analysis From 3-Year Follow-Up of the Phase 3 TOPAZ Study of Durvalumab Plus Gemcitabine and Cisplatin in Biliary Tract Cancer (BTC)” reported the OS by subsequent anticancer therapy use at the 3-year follow-up from the TOPAZ-1 study.

Other posters presented at the CCA Summit investigated gene fusions, driver mutations, and the immune microenvironment. The poster titled “Cholangiocarcinoma With Gene Fusions—Navigating the Genomic Landscape and Outcomes in a Phase I Unit” found that participating in early-phase clinical trials matched with molecular alterations may prolong median OS in eligible patients with CCA compared with patients enrolled in nonmatched trials. Another poster, titled “Driver Mutations Propel Subclonal Evolution in Intrahepatic Cholangiocarcinoma,” found that the acquisition of bona fide driver mutations strongly propels subclonal evolution. Lastly, “Spatial Immune Microenvironment Heterogeneity Between Countries in Intrahepatic Cholangiocarcinoma” analyzed immune microenvironments from patients with intrahepatic CCA from the United States, Korea, and Thailand, and found that intrahepatic CCA in Thai patients exhibits different immune microenvironments compared with samples from US and Korean patients.